Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Repurposing Lesogaberan to Promote Human Islet Cell Survival and β-Cell Replication.

Tian J, Dang H, Hu A, Xu W, Kaufman DL.

J Diabetes Res. 2017;2017:6403539. doi: 10.1155/2017/6403539. Epub 2017 Sep 5.

2.

Reducing Adverse Effects During Drug Development: The Example of Lesogaberan and Paresthesia.

Rydholm H, von Corswant C, Denison H, Jensen JM, Lehmann A, Ruth M, Söderlind E, Aurell-Holmberg A.

Clin Ther. 2016 Apr;38(4):946-60. doi: 10.1016/j.clinthera.2016.02.012. Review.

PMID:
26947796
3.

Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study.

Miner PB Jr, Silberg DG, Ruth M, Miller F, Pandolfino J.

BMC Gastroenterol. 2014 Nov 18;14:188. doi: 10.1186/1471-230X-14-188.

4.

Systemic exposure to the metabolites of lesogaberan in humans and animals: a case study of metabolites in safety testing.

Holmberg AA, Ekdahl A, Weidolf L.

Drug Metab Dispos. 2014 Jun;42(6):1016-21. doi: 10.1124/dmd.113.056614. Epub 2014 Mar 21.

PMID:
24658456
5.

Development of analytical methods for the quantification of metabolites of lesogaberan in a MIST investigation.

Dunér K, Bottner P, Norlén AK.

Biomed Chromatogr. 2014 Mar;28(3):362-8. doi: 10.1002/bmc.3029. Epub 2013 Sep 5.

PMID:
24037996
6.

Identification of the metabolites of lesogaberan using linear trap quadrupole orbitrap mass spectrometry and hydrophilic interaction liquid chromatography.

Ekdahl A, Aurell-Holmberg A, Castagnoli N Jr.

Xenobiotica. 2013 May;43(5):461-7. doi: 10.3109/00498254.2012.725486. Epub 2012 Oct 3.

PMID:
23030741
8.

Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.

Shaheen NJ, Denison H, Björck K, Karlsson M, Silberg DG.

Gut. 2013 Sep;62(9):1248-55. doi: 10.1136/gutjnl-2012-302737. Epub 2012 Jun 23.

PMID:
22730470
9.

Effect of food on the bioavailability of lesogaberan given as an oral solution or as modified-release capsules in healthy male volunteers.

Fransson B, Silberg DG, Niazi M, Miller F, Ruth M, Holmberg AA.

Int J Clin Pharmacol Ther. 2012 Apr;50(4):307-14.

PMID:
22456303
10.

Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'.

Boeckxstaens GE, Denison H, Jensen JM, Lehmann A, Ruth M.

Curr Opin Pharmacol. 2011 Dec;11(6):630-3. doi: 10.1016/j.coph.2011.10.011. Epub 2011 Oct 27. Review.

PMID:
22036168
11.

Pharmacokinetic profile of lesogaberan (AZD3355) in healthy subjects: a novel GABA(B)-receptor agonist reflux inhibitor.

Niazi M, Skrtic S, Ruth M, Holmberg AA.

Drugs R D. 2011;11(1):77-83. doi: 10.2165/11590310-000000000-00000.

12.

A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial.

Boeckxstaens GE, Beaumont H, Hatlebakk JG, Silberg DG, Björck K, Karlsson M, Denison H.

Gut. 2011 Sep;60(9):1182-8. doi: 10.1136/gut.2010.235630. Epub 2011 Mar 14.

PMID:
21402616
13.

Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects.

Niazi M, Silberg DG, Miller F, Ruth M, Holmberg AA.

Drugs R D. 2010;10(4):243-51. doi: 10.2165/11588180-000000000-00000.

14.

Inhibition of transient lower esophageal sphincter relaxation in GERD: will lesogaberan advance the field?

Falk GW.

Gastroenterology. 2010 Aug;139(2):377-9. doi: 10.1053/j.gastro.2010.06.028. Epub 2010 Jun 23. No abstract available.

PMID:
20600061
15.

Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease.

Boeckxstaens GE, Beaumont H, Mertens V, Denison H, Ruth M, Adler J, Silberg DG, Sifrim D.

Gastroenterology. 2010 Aug;139(2):409-17. doi: 10.1053/j.gastro.2010.04.051. Epub 2010 May 5.

PMID:
20451523
16.

Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects.

Boeckxstaens GE, Rydholm H, Lei A, Adler J, Ruth M.

Aliment Pharmacol Ther. 2010 Jun;31(11):1208-17. doi: 10.1111/j.1365-2036.2010.04283.x. Epub 2010 Mar 4.

17.

The novel, peripherally restricted GABAB receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs.

Brändén L, Fredriksson A, Harring E, Jensen J, Lehmann A.

Eur J Pharmacol. 2010 May 25;634(1-3):138-41. doi: 10.1016/j.ejphar.2010.02.015. Epub 2010 Feb 20.

PMID:
20176012
18.

Supplemental Content

Loading ...
Support Center